All-In PodcastE1: US Response to COVID-19 & Impact on Startups, VC & Public Markets with David Friedberg
Jason Calacanis on cOVID-19, Markets, and Startups: Data, Testing, and Economic Reckoning.
In this episode of All-In Podcast, featuring Jason Calacanis and Chamath Palihapitiya, E1: US Response to COVID-19 & Impact on Startups, VC & Public Markets with David Friedberg explores cOVID-19, Markets, and Startups: Data, Testing, and Economic Reckoning The episode explores the early U.S. response to COVID-19 across three fronts: public health, government policy, and financial markets. David Friedberg argues that policy is being made on incomplete data, especially undercounted asymptomatic cases, which likely overstates fatality rates and justifies overly blunt shutdowns.
At a glance
WHAT IT’S REALLY ABOUT
COVID-19, Markets, and Startups: Data, Testing, and Economic Reckoning
- The episode explores the early U.S. response to COVID-19 across three fronts: public health, government policy, and financial markets. David Friedberg argues that policy is being made on incomplete data, especially undercounted asymptomatic cases, which likely overstates fatality rates and justifies overly blunt shutdowns.
- The hosts push for massive, rapid rollout of antibody and PCR testing, emergency use of promising treatments, and more targeted containment focused on high‑risk groups to avoid economic collapse. They also dissect the knock‑on effects for startups, venture capital, and capital markets, predicting a long funding winter and forced deleveraging.
- A broader critique emerges of corporate leverage, stock buybacks, and fragile global supply chains, with calls for “compassionate capitalism,” more resilient national infrastructures, and stricter constraints on financial excess. They close with cautious optimism that parts of the economy could reopen within weeks if testing and data improve quickly.
IDEAS WORTH REMEMBERING
7 ideasPolicy is being set on bad denominators; mass antibody testing is urgent.
Friedberg cites data from Korea, China, cruise ships, and NBA players suggesting 20–80% of infections may be asymptomatic, which would drastically lower true fatality rates. Without broad IgG/IgM antibody testing of the general population, shutdown policies may be far more draconian than necessary.
Deploy cheap, promising treatments under emergency rules instead of waiting for perfect trials.
Drugs like remdesivir and chloroquine show early signals of efficacy abroad, but U.S. regulators focus on traditional blinded trials. The hosts argue that in a crisis, the FDA should mass-produce and release these drugs for physician‑guided use, accepting more risk to potentially cut fatalities by multiples.
Design smarter, targeted containment instead of blanket, open‑ended lockdowns.
They propose focusing strict isolation on high‑risk groups (e.g., elderly, those with comorbidities), combined with random population antibody testing and rapid treatment, to gradually reopen zones of “cleared” people and restart economic activity faster.
Startups must immediately pivot from growth to survival and maximize runway.
Founders are urged to assume fundraising will be extremely difficult for 18–36 months: close any live rounds now, cut burn aggressively (including founder pay cuts), refocus on unit economics, and adapt strategy to where customers will be post‑shock rather than chasing pre‑crisis growth plans.
VCs and LPs are being forced to de‑risk, which will sharply constrict venture funding.
With public portfolios down and illiquid venture stakes suddenly overweight, LPs will pressure VCs to mark down assets and avoid new capital calls. This likely means fewer follow‑on rescues, harsher selection, and many “default dead” startups not being saved.
Bailouts should wipe out equity and curb financial engineering, not reward it.
Using airlines as an example, the hosts criticize firms that spent nearly all free cash flow on buybacks instead of buffers, then line up for taxpayer bailouts. They advocate nationalizing distressed firms, wiping out shareholders, capping buybacks/CEO pay, and channeling future re‑IPO proceeds back to the public.
The crisis will likely push economies from hyper‑efficient globalization toward resilient national systems.
They expect more on‑shore production (even at higher cost), diversified supply chains, and less tolerance for brittle, just‑in‑time systems—from iPhones to food and medical gear—alongside stricter limits on leverage and speculative financial behavior.
WORDS WORTH SAVING
5 quotesWe’re still racing and acting from a policy basis as if 2–4% of people that get this are going to die—and that may not actually be true based on what we’re seeing in the last week.
— David Friedberg
Right now we’re in the worst place, which is isolation and confinement in the absence of data.
— Chamath Palihapitiya
Survival matters more than growth right now.
— David Friedberg
Rule number one of our business is to not go out of business. Rule number two is not to forget rule number one.
— Chamath Palihapitiya (paraphrasing Warren Buffett)
We have been so hell‑bent on the use of leverage and accounting tricks to enrich a few at the sake of the many, and this is the right time where you should nationalize some of these businesses.
— Chamath Palihapitiya
QUESTIONS ANSWERED IN THIS EPISODE
5 questionsIf large‑scale antibody testing confirms very high asymptomatic spread, how should governments redesign COVID-19 policy and messaging in real time?
The episode explores the early U.S. response to COVID-19 across three fronts: public health, government policy, and financial markets. David Friedberg argues that policy is being made on incomplete data, especially undercounted asymptomatic cases, which likely overstates fatality rates and justifies overly blunt shutdowns.
Where should regulators draw the line between speed and safety when authorizing unproven treatments during a public health emergency?
The hosts push for massive, rapid rollout of antibody and PCR testing, emergency use of promising treatments, and more targeted containment focused on high‑risk groups to avoid economic collapse. They also dissect the knock‑on effects for startups, venture capital, and capital markets, predicting a long funding winter and forced deleveraging.
How can startups practically plan for 24–36 months of constrained capital without permanently crippling their long‑term potential?
A broader critique emerges of corporate leverage, stock buybacks, and fragile global supply chains, with calls for “compassionate capitalism,” more resilient national infrastructures, and stricter constraints on financial excess. They close with cautious optimism that parts of the economy could reopen within weeks if testing and data improve quickly.
What specific conditions or metrics should determine whether a corporate bailout wipes out equity versus simply providing bridge liquidity?
In moving from global efficiency to national resiliency, which sectors (healthcare, food, tech hardware, finance) should be prioritized for on‑shoring or redundancy, and who should pay for that shift?
EVERY SPOKEN WORD
Install uListen for AI-powered chat & search across the full episode — Get Full Transcript
Get more out of YouTube videos.
High quality summaries for YouTube videos. Accurate transcripts to search & find moments. Powered by ChatGPT & Claude AI.
Add to Chrome